Adrenoleukodystrophy (ALD) describes any of several closely related inheritable disorders that affect the adrenal glands, nervous system, and testes. Adrenoleukodystrophy is transmitted as an X-linked trait (the neonatal form is by autosomal recessive transmission and is a different disease). It results in the accumulation of long chain fatty acids in the nervous system, adrenal gland, and testes.

A screening test can identify carriers of the ALD/AMN gene with 99% accuracy. The test requires only a blood sample. Please contact Kennedy Krieger for more information on having the blood test.

Yes. Although women who carry the ALD gene mutation do not develop the brain disease, some display mild symptoms of the disorder. These symptoms usually develop after age 35, and primarily include progressive stiffness, weakness, or paralysis of the lower limbs, numbness, pain in the joints, and urinary problems.

One group at the University of Minnesota has used a combination of stem cell transplantation and therapy with a drug called Mucomyst, approved by the FDA to treat cystic fibrosis and acetaminophen overdose. This was tried on three boys whose disease had already progressed past the point when bone marrow transplant is generally thought to be effective. So far, MRI scans show no further progression of the disease, and the approach is being tried in additional patients.

It depends. A man with AMN/ALD does not pass along the mutated gene to his sons, so his sons will be free of the disease. All of his daughters, however, will carry the mutation.

Yes. With each conception, there is a 50-50 chance of passing on the defect on the X chromosome. If the defect is passed on, a female child will be a carrier, and a male child will have the disease. Prenatal testing can identify, during pregnancy. whether the defective gene has been passed on.

In rare cases, yes. About 5% to 7% of ALD/AMN cases arise from "de novo" genetic mutations-mutations that were not present in the child's parents.

It depends on their relationship to the person who has ALD. For example, if a boy has ALD, his mother should be tested for the mutation, as should all of his siblings. His mother's siblings-especially sisters-should be tested as well, since they may also have inherited the ALD mutation and be at risk for passing it on to their children. Genetic counselors can best advise you as to who in your family should be tested.

A man who has ALD or AMN will not pass the disease gene to any sons, but all of his daughters will carry the mutation. A woman who carries the mutated gene has a 50-50 chance of transmitting the mutation in each pregnancy. To avoid passing along the gene, there are two options: in vitro fertilization with preimplantation genetic diagnosis, which would avoid implanting embryos with ALD.

present, there are only two treatments for ALD: Lorenzo's oil and stem cell transplantation using either bone marrow stem cells or umbilical cord blood stem cells. These treatments appear to be most effective if they are used before the onset of symptoms. There are currently two sources for transplanted stem cells: umbilical cord blood (UCBT) or bone marrow (BMT).

There are territories available for purchase, and some territories available for resale. For a list of available territories, go to Available Territories. Contact the Franchise Development department at 800.755.6697 or use our Contact Form.

It depends on the type of AMN that he has. In some people, AMN affects the spinal cord only, while in others, it affects both the spinal cord and the brain. About 54% of patients with AMN have normal brain function, while the other 46% have some type of brain involvement. Magnetic resonance imaging (MRI) can determine if the brain is affected by the disease. Patients without cerebral involvement have a significantly better prognosis than those in whom the brain is affected.

In some unusual cases-about 5% to 7% of all cases, according to research published by the late Hugo Moser, M.D., a pioneer in ALD studies-ALD arises from "de novo" mutations-genetic mutations that were not present in the parents.

Riluzole is a drug approved to treat amyotrophic lateral sclerosis (ALS). Patrick Aubourg, a professor of pediatrics at Hospital Saint-Vincent de Paul in Paris, has been studying Riluzole to see if it has any effectiveness in treating AMN.

Get a magnetic resonance imaging (MRI) scan of the child's brain. This will tell you the extent of the progression of the disease, and determine next steps. It will also provide a baseline for you and physicians to use to compare with future MRI scans, which are generally performed at 6 ? 12 month intervals. Have your child tested for adrenal insufficiency (Addison's disease). This is usually done by a pediatric endocrinologist. Addison's disease is generally associated with ALD.

In general, boys are candidates for transplant if they have visible lesions on an MRI, but are showing no neurological symptoms, or at most early symptoms. Boys with an MRI Loes score less than 8 or 9 are usually considered suitable for transplantation.

The onset of childhood cerebral ALD is usually between ages four and ten years. The prognosis is generally poor, particularly if the disease is not correctly diagnosed before significant symptoms develop. Many of these children die within one and ten years of the onset of symptoms. There are some treatment options (Lorenzo's oil and stem cell transplants) that may alter this prognosis, but they are not guarantees.

A boy inherits the mutated ALD gene from his mother. However, it is possible for a boy to have ALD if his mother does not carry the mutated gene. This is because s an estimated 5%-7% of cases are de novo mutations, meaning that the gene mutation arose spontaneously in the child when it was not present in the mother.

Recent studies indicate that Lorenzo's oil may be effective in helping to prevent the onset of the disease's symptoms in boys who have the genetic mutation that causes ALD. It is unclear, however, if Lorenzo's oil can be effective as a treatment once symptoms have already begun to develop.

ALD = Annual Leave Destination, at your interview it will be determined where this will be. It is based on a number of personal items including: Nationality in Passport, Permanent address, residency rights, property ownership, voting rights, etc. ALD will be the place that we will issue the ALT to. If your ALD is not near an Emirates network, the company will determine the nearest International Airport to your country of citizenship or nationality.